Engitix Therapeutics
Engitix Therapeutics is a London-based biotech company developing treatments for fibrosis and solid tumors using its human extracellular matrix discovery platform. The company has raised $85M in Series A funding and employs 63 people.
The growth story
Engitix Therapeutics grew from 25 to 63 employees between 2020 and 2026, raising $85M along the way, most recently a Series A in January 2026.
About
Engitix Therapeutics develops therapies for fibrosis and solid tumors by leveraging its proprietary human extracellular matrix platform. This technology enables the study of tissue- and disease-specific targets and biomarkers, aiming to improve drug discovery success rates.
The company, founded in 2016, has secured $85M in Series A funding, indicating strong investor confidence. With 63 employees, Engitix is scaling its research efforts, focusing on fibrosis and oncology treatments.
Founders and leadership
Engitix Therapeutics is led by a research-focused team, with 24 employees dedicated to research, making it the largest function within the company. The leadership spans expertise in biotech and drug discovery.
The Engitix Therapeutics org chart
Giuseppe Mazza (Co-Founder and CEO) leads 22 mapped leaders with 4 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 33 (+3% YoY), Business Development 10 (+11% YoY), Information Technology 3 (+50% YoY), Engineering 3 (0% YoY), Finance 3 (0% YoY).
Talent flow
Engitix recruits heavily from top UK institutions, with Imperial College London and UCL being the most common sources. Alumni often move to roles in biotech firms like GSK and Econic Biosciences.
Most common previous employers of Engitix Therapeutics staff: Imperial College London (10), The Institute of Cancer Research (8), UCL (7), Novartis (5), King's College London (5), Johnson & Johnson (4). Former Engitix Therapeutics employees most often moved to Econic Biosciences (2), GSK (2), Tubulis (1), BioDiscovery Consulting (1), OncoBioinformatics Consulting (1), Khanda Therapeutics (1).
Alumni worth knowing
Web traffic
Traffic mix: 0% direct, 0% search, 0% social, 0% paid.
What this company is made of
Most common skills at Engitix Therapeutics: Molecular Biology (28), Research Skills (25), Cell Culture (24), Data Analysis (22), Teamwork (18), Drug Discovery (17), Cell Biology (16), Communication (16).
Where the team actually sits
Engitix Therapeutics people are concentrated in England, United Kingdom (40), United Kingdom (8), London Area, United Kingdom (3), Greater Philadelphia (2). 2 offices on record.
Search footprint
Engitix Therapeutics attracts about 23 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 2 ranking keywords and lost 3 in the last period.
What employees say
- Compensation
- 3.90 / 5
- Career opportunities
- 4.00 / 5
- Senior management
- 3.80 / 5
- Work-life balance
- 4.30 / 5
Frequently asked
Engitix Therapeutics has 63 employees as of September 2026.
Engitix Therapeutics has raised $85M in total, most recently a Series A round in January 2026.
Engitix Therapeutics was founded in 2016 by Giuseppe Mazza, Massimo Pinzani.
Giuseppe Mazza (Co-Founder and CEO) sits at the top of Engitix Therapeutics's reporting structure, with 4 direct reports.
The most common previous employers of current Engitix Therapeutics staff are Imperial College London (10 people), The Institute of Cancer Research (8 people), UCL (7 people).
Former Engitix Therapeutics employees most often move to Econic Biosciences (2), GSK (2), Tubulis (1).
Engitix Therapeutics attracts about 23 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Engitix Therapeutics staff are Molecular Biology, Research Skills, Cell Culture, Data Analysis, Teamwork.
Engitix Therapeutics staff are concentrated in England, United Kingdom (40), United Kingdom (8), London Area, United Kingdom (3).
Engitix Therapeutics has about 33 people in Research, up 3% over the past year, as of September 2026.
Engitix Therapeutics has about 10 people in Business Development, up 11% over the past year, as of September 2026.
Computed from 58 current and 53 former Engitix Therapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.